news
Breast cancer survival up, but not from screening, researchers say
Danish researchers are challenging the conventional wisdom that breast cancer screening is solely responsible for improved survival rates. They argue that advancements in treatment, particularly better chemotherapy and hormone therapy, are the real drivers behind more women beating the disease. This take has major implications for current screening programs and policy debates.
Danish researchers are challenging the conventional wisdom that breast cancer screening is solely responsible for improved survival rates. They argue that advancements in treatment, particularly better chemotherapy and hormone therapy, are the real drivers behind more women beating the disease. This take has major implications for current screening programs and policy debates.
The architecture take
This is a big one. Three Danish researchers just dropped a scientific bombshell: those incredible breast cancer survival stats? Not primarily thanks to screening, they claim. Instead, the real heroes are the treatments that kick in after diagnosis — things like smarter chemotherapy and hormone therapies that actually target the cancer. The numbers look good because we're better at killing the cancer once we find it, not because we're finding it earlier through mammograms. I always tell people to ask: what's the actual mechanism? Here, it's not early detection alone, it's effective intervention. This puts a spotlight on the burden of unnecessary biopsies and false positives from screening, too. If this research holds up, it means we need to rethink where we're investing our resources and focus on the therapies that genuinely improve outcomes, not just the diagnostic tools. We might be over-indexing on prevention when treatment is the game-changer.